Dyne Therapeutics, Inc. (DYN)

Market Cap	2.05B
Revenue (ttm)	n/a
Net Income (ttm)	-235.94M
Shares Out	81.11M
EPS (ttm)	-3.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	144,703
Open	25.63
Previous Close	25.44
Day's Range	25.20 - 25.92
52-Week Range	6.40 - 30.27
Beta	0.95
Analysts	Strong Buy
Price Target	37.38 (+48.16%)
Earnings Date	May 9, 2024

About DYN

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2020
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: DYN

Analyst Forecast

According to 8 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price forecast is $37.38, which is an increase of 48.16% from the latest price.

Price Target

$37.38

(48.16% upside)

Analyst Consensus: Strong Buy